Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05223387

Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial

Anthogyr Axiom Tissue-Level implants and corresponding Multi-Unit abutments recently enriched the available product range for dental surgeons. This Post-Market Clinical Follow-Up study aims at confirming the safety and performance of these products. The comparison with similar Anthogyr Axiom Bone-level implants will provide additional information on the effect of platform-switching in bone level maintenance for single and two-piece design at the implant level.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculdade de Medicina Dentária da Universidade do Porto, Porto, Portugal

Loading trial locations.

About this study

This is a multicenter, comparative, prospective, randomized, controlled, post-market clinical follow-up (PMCF) study.

The total study duration for each patient should be 3 years. Anthogyr Axiom TL and BL REG and corresponding Multi-Unit abutments will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.

In total 8 visits per patient are scheduled in this study

Implant and prosthesis survival, success, bone level changes, patient reported outcome, soft tissue assessment and adverse events (AEs) will be assessed.

The investigational devices are CE-(Conformité Européenne, meaning European Conformity) marked product.

3 centers will participate in Spain and Portugal.

The study and any amendments will be performed as far as possible according to International Organization for Standardization (ISO) 14155 and conform to the Declaration of Helsinki (last revision Fortaleza 2013) and local legal and regulatory requirements.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have voluntarily signed the Informed Consent Form before any study related procedures are performed, are willing and able to attend scheduled follow-up visits and agree that the pseudonymized data are collected and analyzed.
  • Patients must be males or females who are a minimum of 18 years of age.
  • Patients with a minimum of 4 weeks history of edentulism in the study area, in need of a multiple teeth replacement with dental implants
  • Patients with complete soft tissue coverage of the socket at implant placement

Exclusion criteria

  • Patients with inadequate bone volume and/or quality: Only minor and simultaneous bone augmentation procedures will be allowed where required for regeneration of minor defects. Insufficient bone volume and quality is defined as secondary exclusion criterion and the patient will be considered as screening failure.
  • Uncontrolled systemic disease that would interfere with dental implant therapy (e.g. uncontrolled diabetes)
  • Any contraindications for oral surgical procedures
  • History of local irradiation therapy in the head / neck area
  • Patients who are currently heavy smokers (defined >10 cigarettes per day or >1 cigar per day), or have ≥ 20 pack years who use chewing tobacco
  • Medical conditions requiring chronic high dose steroid therapy or high dose anti-resorptive treatment
  • Subjects who have undergone administration of any investigational device within 30 days of enrolment in the study
  • Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
  • Cognitive impairment that would interfere with the ability to perform adequate oral hygiene (assessed by Ottawa 3DY scale)
  • Patients with chronic pain

Treatment and study plan

Axiom TL REG

Device

Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.

In each case, the MU abutment will be placed immediately after implant placement.

Multi-Unit abutments are used to fix the prosthesis

Other names: Multi-Unit abutment

Axiom BL REG

Device

Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.

In each case, the MU abutment will be placed immediately after implant placement.

Multi-Unit abutments are used to fix the prosthesis

Other names: Multi-Unit abutment

Primary outcomes

  1. Marginal Bone Level Change

    Time frame: 6 months,12 months, and 3 years after loading

    Change in crestal bone level measured by analysis of standardized peri-apical xrays [mm].

Secondary outcomes

  1. Implant survival

    Time frame: 6 months,12 months, and 3 years after loading

    A surviving implant is an implant that is in place at the time of evaluation.

  2. Prosthesis Survival

    Time frame: 6 months,12 months, and 3 years after prosthesis placement

    a surviving prosthesis is a prosthesis that is not broken at the time of evaluation.

  3. 14 item Oral Health Impact Profile (OHIP-14)

    Time frame: screening visit, 6, 12 months and 3 years after loading

    he local language version of the OPHIP-14 is a self-reported questionnaire that measures dysfunction, discomfort and disability attributed to oral conditions. The questionnaire focuses on seven dimensions of impact: Functional limitation; Pain; Psychological discomfort; Physical disability; Psychological disability; Social disability; Handicap. The patients will be asked to respond according to frequency of impact on a 5-point Likert scale coded never (score 0), hardly ever (score 1), occasionally (score 2), fairly often (score 3) and very often (score 4).

Other outcomes

  1. Adverse Events

    Time frame: 3 years after inclusion

    Adverse Events will be recorded at every visit. Adverse Events will be recorded at every visit.

  2. Device Deficiencies

    Time frame: 3 years after inclusion

    Adverse Events will be recorded at every visit. Any device complications and deficiencies will be recorded as Device Deficiencies.

Sponsors and collaborators

Lead sponsor

Anthogyr

Industry

Registry information

Acronym: IBERICA

Important dates

Study start
2022
Primary completion
2025
Study completion
2027
First posted
Feb 4, 2022
Registry last updated
Mar 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.